AZ-NHIS’s dramatic conclusion on Tagrisso drug price negotiation

Published: 2017-11-09 16:01:14

Updated: 2017-11-09 16:02:09

The AstraZeneca’s non-small cell lung cancer treatment Tagrisso(generic name: osimertinib), whose negotiation was broken down twice, finally passed the drug price negotiation.

The National Health Insurance Service(NHIS) and AstraZeneca Korea have dramatically concluded the 3rd drug price negotiation for Tagrisso between the afternoon and midnight on the 7th.

The NHIS and the company had negot...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.